BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29089230)

  • 61. Prospective virtual screening for novel p53-MDM2 inhibitors using ultrafast shape recognition.
    Patil SP; Ballester PJ; Kerezsi CR
    J Comput Aided Mol Des; 2014 Feb; 28(2):89-97. PubMed ID: 24554192
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
    Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
    Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Structure-activity relationship study of 4-substituted piperidines at Leu26 moiety of novel p53-hDM2 inhibitors.
    Tian Y; Ma Y; Gibeau CR; Lahue BR; Shipps GW; Strickland C; Bogen SL
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2735-8. PubMed ID: 27080185
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.
    Hardcastle IR; Ahmed SU; Atkins H; Farnie G; Golding BT; Griffin RJ; Guyenne S; Hutton C; Källblad P; Kemp SJ; Kitching MS; Newell DR; Norbedo S; Northen JS; Reid RJ; Saravanan K; Willems HM; Lunec J
    J Med Chem; 2006 Oct; 49(21):6209-21. PubMed ID: 17034127
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.
    Gessier F; Kallen J; Jacoby E; Chène P; Stachyra-Valat T; Ruetz S; Jeay S; Holzer P; Masuya K; Furet P
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3621-5. PubMed ID: 26141769
    [TBL] [Abstract][Full Text] [Related]  

  • 66. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
    Sirous H; Chemi G; Campiani G; Brogi S
    Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Inhibition of p53-Murine Double Minute 2 (MDM2) Interactions with 3,3'-Spirocyclopentene Oxindole Derivatives.
    Gicquel M; Gomez C; Garcia Alvarez MC; Pamlard O; Guérineau V; Jacquet E; Bignon J; Voituriez A; Marinetti A
    J Med Chem; 2018 Oct; 61(20):9386-9392. PubMed ID: 30221935
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
    Ding K; Lu Y; Nikolovska-Coleska Z; Wang G; Qiu S; Shangary S; Gao W; Qin D; Stuckey J; Krajewski K; Roller PP; Wang S
    J Med Chem; 2006 Jun; 49(12):3432-5. PubMed ID: 16759082
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Targeted Degradation of MDM2 as a New Approach to Improve the Efficacy of MDM2-p53 Inhibitors.
    Wurz RP; Cee VJ
    J Med Chem; 2019 Jan; 62(2):445-447. PubMed ID: 30575392
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.
    Shangary S; Ding K; Qiu S; Nikolovska-Coleska Z; Bauer JA; Liu M; Wang G; Lu Y; McEachern D; Bernard D; Bradford CR; Carey TE; Wang S
    Mol Cancer Ther; 2008 Jun; 7(6):1533-42. PubMed ID: 18566224
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Structure-based design of novel inhibitors of the MDM2-p53 interaction.
    Rew Y; Sun D; Gonzalez-Lopez De Turiso F; Bartberger MD; Beck HP; Canon J; Chen A; Chow D; Deignan J; Fox BM; Gustin D; Huang X; Jiang M; Jiao X; Jin L; Kayser F; Kopecky DJ; Li Y; Lo MC; Long AM; Michelsen K; Oliner JD; Osgood T; Ragains M; Saiki AY; Schneider S; Toteva M; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH
    J Med Chem; 2012 Jun; 55(11):4936-54. PubMed ID: 22524527
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
    Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
    Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Double-edged swords as cancer therapeutics: novel, orally active, small molecules simultaneously inhibit p53-MDM2 interaction and the NF-κB pathway.
    Zhuang C; Miao Z; Wu Y; Guo Z; Li J; Yao J; Xing C; Sheng C; Zhang W
    J Med Chem; 2014 Feb; 57(3):567-77. PubMed ID: 24428757
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy.
    Harakandi C; Nininahazwe L; Xu H; Liu B; He C; Zheng YC; Zhang H
    Bioorg Chem; 2021 Nov; 116():105273. PubMed ID: 34474304
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Novel p-Functionalized Chromen-4-on-3-yl Chalcones Bearing Astonishing Boronic Acid Moiety as MDM2 Inhibitor: Synthesis, Cytotoxic Evaluation and Simulation Studies.
    Bhatia RK; Singh L; Garg R; Kaur M; Yadav M; Madan J; Kancherla S; Pissurlenkar RRS; Coutinho EC
    Med Chem; 2020; 16(2):212-228. PubMed ID: 31146672
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Angler Peptides: Macrocyclic Conjugates Inhibit p53:MDM2/X Interactions and Activate Apoptosis in Cancer Cells.
    Philippe GJ; Mittermeier A; Lawrence N; Huang YH; Condon ND; Loewer A; Craik DJ; Henriques ST
    ACS Chem Biol; 2021 Feb; 16(2):414-428. PubMed ID: 33533253
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
    Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
    Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bioorthogonal Probes for the Study of MDM2-p53 Inhibitors in Cells and Development of High-Content Screening Assays for Drug Discovery.
    D'Alessandro PL; Buschmann N; Kaufmann M; Furet P; Baysang F; Brunner R; Marzinzik A; Vorherr T; Stachyra TM; Ottl J; Lizos DE; Cobos-Correa A
    Angew Chem Int Ed Engl; 2016 Dec; 55(52):16026-16030. PubMed ID: 27874234
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The isolation, total synthesis and structure elucidation of chlorofusin, a natural product inhibitor of the p53-mDM2 protein-protein interaction.
    Clark RC; Lee SY; Searcey M; Boger DL
    Nat Prod Rep; 2009 Apr; 26(4):465-77. PubMed ID: 19642417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.